Evidence map›Paper›PMID 29085408›Full record

ArticleAfrican health sciences2017

Multidrug and vancomycin resistance among clinical isolates of

Olajuyigbe Olufunmiso, Ikpehae Tolulope, Coopoosamy Roger

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African health sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Global prevalence of macrolide-resistantFrontiers in microbiology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Methicillin and vancomycin-resistantInfection prevention in practice · 2024
    Article
  12. Review
  13. Molecular Confirmation of Vancomycin-ResistantInternational journal of microbiology · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Olajuyigbe OlufunmisoDepartment of Microbiology, School of Sciences and Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
Ikpehae TolulopeDepartment of Microbiology, School of Sciences and Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
Coopoosamy RogerDepartment of Nature Conservation, Faculty of Natural Sciences, Mangosuthu University of Technology, Durban, South Africa.
Mangosuthu University of Technology · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgrounds

methodsSwabs were collected from different infection sites from out-patients in three teaching hospitals from October 2015 to May, 2016. The antibiotic-susceptibility test was carried out with selected antibiotics usually administered anti-microbials in the treatment of infections in these hospitals. The prevalence of multi-drug and vancomycin resistance strains of

resultsThe result showed (165)82.5% of the isolates were resistant to ≥3 antibiotics tested. They were highly resistant to ceftazidime 180(90%), cloxacillin 171(85.6%) and augmentin 167(83.3%), but susceptible to ofloxacin 150(75%), gentamicin 142(71.7%), erythromycin 122(61.1%), ceftriaxone 111(55.6%) and cefuroxime 103(51.7%). All the isolates from the HVS were all multidrug resistant strains. While (56)90.16% were multidrug resistant (MDR) in urine samples, followed by (8)88.89% MDR strains in sputum, (37)88.81% MDR strains in semen, (49)71.64% MDR strains in wounds and (6)60% MDR strains in ear swabs samples. Although (147)73.5% of the isolates were vancomycin susceptible

conclusionsThe high percentage of the VRSA could have resulted from compromising treatment options and inadequate antimicrobial therapy. The implication, infections caused by VRSA would be difficult to treat with vancomycin and other effective antibiotics of clinical importance. Ensuring proper monitoring of drug administration will, therefore, enhance the legitimate role of vancomycin as an empiric choice for both prophylaxis against and treatment of

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsNigeriaStaphylococcal InfectionsStaphylococcus aureusVancomycinAnti-Bacterial AgentsVancomycinagar dilutionBacterial resistancesusceptibility studiesvancomycin resistant S. aureus

Identifiers

PMID29085408
PMCPMC5656204
OpenAlexW2754862647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.